论文部分内容阅读
目的:探讨雌/孕激素受体(ER/PR)和eerbB-2在新辅助化疗乳腺癌组织中的表达及临床意义。方法: 采用新辅助化疗方案(CEF或CTF方案)治疗89例乳腺癌患者,用免疫组织化学法检测ER/PR及cerbB-2在乳腺癌组织中的表达情况。结果:89例新辅助化疗总有效率达89.9%,其中完全缓解29例(32.6%),部分缓解51例(57.3%),病理完全缓解(pCR)17.9%,疾病稳定9例(10.1%),无恶化病例;激素受体表达阴性者病理完全缓解率达27.7%,而激素受体阳性表达者病理完全缓解率仅为7.1%(P<0.05),cerbB-2表达与化疗疗程无关。结论: 激素受体阴性者对新辅助化疗的敏感性较高,激素受体可能成为评价和判断新辅助化疗乳腺癌患者临床疗效和预后的重要参考指标。
Objective: To investigate the expression and clinical significance of estrogen / progesterone receptor (ER / PR) and eerbB-2 in neoadjuvant chemotherapy of breast cancer. Methods: 89 patients with breast cancer were treated with neoadjuvant chemotherapy (CEF or CTF regimen). The expression of ER / PR and cerbB-2 in breast cancer tissues was detected by immunohistochemistry. Results: The total effective rate of neoadjuvant chemotherapy in 89 cases was 89.9%. Complete remission was achieved in 29 cases (32.6%), partial remission in 51 cases (57.3%), complete remission (pCR) in 17.9% and stable disease in 9 cases (10.1% , No worsening cases. The rate of pathological complete remission was 27.7% in patients with negative hormone receptor expression and 7.1% (P <0.05) in patients with positive hormone receptor expression. The expression of cerbB-2 was not related to the course of chemotherapy. Conclusion: Hormone receptor negative patients are more sensitive to neoadjuvant chemotherapy. Hormone receptor may be an important reference index for evaluating and judging the clinical efficacy and prognosis of patients with neoadjuvant chemotherapy.